Clinical Trials Using CCR2/CCR5 Antagonist BMS-813160
Clinical trials are research studies that involve people. The clinical trials on this list are studying CCR2/CCR5 Antagonist BMS-813160. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors
This study will evaluate the safety profile, tolerability, PK, PD, and preliminary efficacy of BMS-813160 alone or in combination with either chemotherapy or nivolumab in participants with metastatic colorectal and pancreatic cancers.
Location: 19 locations
A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma
The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer
Location: 14 locations
CCR2 / CCR5 Antagonist BMS-813160, Nivolumab, Gemcitabine Hydrochloride, and Nab-Paclitaxel in Treating Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer
This phase I / II trial studies the side effects of CCR2 / CCR5 antagonist BMS-813160, nivolumab, gemcitabine hydrochloride, and nab-paclitaxel and how well they work in treating patients with pancreatic cancer that can be borderline removed by surgery (resectable) or has spread to nearby tissue or lymph nodes (locally advanced). CCR2 / CCR5 antagonist BMS-813160 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Nivolumab may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as gemcitabine hydrochloride and nab-paclitaxel, may work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving CCR2 / CCR5 antagonist BMS-813160, nivolumab, gemcitabine hydrochloride, and nab-paclitaxel may work better in treating patients with pancreatic cancer.
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri